Patrick Phillips, PhD, MS, MA

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Address2540 23rd Street, #4725
San Francisco CA 94110
ORCID ORCID Icon0000-0002-6336-7024 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Clare College, University of Cambridge, UKBA Hons2003Mathematics
    University of Reading, UKMSc2005Biometry
    Clare College, University of Cambridge, UKMA2007Mathematics
    London School of Hygiene and Tropical Medicine, University of London, UKPhD2009Medical Statistics
    London School of Hygiene and Tropical Medicine, University of London, UKPDip2010Postgraduate Diploma of the LSHTM by research in Epidemiology and Population Health

    Collapse Overview 
    Collapse Overview
    As part of the UCSF Center for Tuberculosis, I am Associate Professor in Residence in the Division of Pulmonary and Critical Care Medicine with a secondary appointment in the Department of Epidemiology and Biostatistics. Prior to 2017 I was senior statistician at the MRC Clinical Trials Unit at UCL in London.

    The objective of my research is to design, implement, and optimize clinical trials for new treatments for tuberculosis in order to deliver safer and more efficacious regimens for patients. I lead the Trial Design and Statistics core of the PanACEA consortium evaluating novel regimens for the treatment of TB, am consultant statistician for the US CDC-funded TB Trials Consortium (TBTC), and a member of the ACTG TB Transformative Science Steering Group. I have worked on late-phase clinical trials in tuberculosis for more than fifteen years, most recently as trial statistician in the STREAM Stage 1 and the TBTC/ACTG S31/A5349 phase III trials and vice-chair of ACTG A5414 SPECTR-TB. Ongoing methodological areas of interest include the evaluation and use of surrogate endpoints, the conduct and analysis of non-inferiority trials and trial design with a focus on adaptive designs. I am an associate editor for the journal BMC Trials.
    Collapse Global Health Equity

    Collapse Research 
    Collapse Research Activities and Funding
    Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial
    NIH R61HL146365Sep 15, 2019 - Aug 31, 2021
    Role: Co-Investigator
    Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment
    NIH U01AI100805Aug 9, 2013 - Jul 31, 2017
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial. Trials. 2024 Mar 12; 25(1):180. Weir IR, Dufault SM, Phillips PPJ. PMID: 38468320; PMCID: PMC10929173.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS Med. 2024 Feb 20; 21(2):e1004356. Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. PMID: 38377166.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics. Clin Infect Dis. 2024 Feb 02. Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T, Asege L, Bukirwa A, Kato JB, Katumba D, Kisakye E, Mangeni W, Mwebe S, Nakaye M, Nassuna I, Nyawere J, Nakaweesa A, Cook C, Phillips P, Nalugwa T, Bachman CM, Semitala FC, Weigl BH, Connelly J, Worodria W, Cattamanchi A. PMID: 38306491.
      View in: PubMed   Mentions:    Fields:    
    4. Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa. Lancet Glob Health. 2024 Feb; 12(2):e226-e234. Gupta-Wright A, Ha H, Abdulgadar S, Crowder R, Emmanuel J, Mukwatamundu J, Marcelo D, Phillips PPJ, Christopher DJ, Nhung NV, Theron G, Yu C, Nahid P, Cattamanchi A, Worodria W, Denkinger CM, R2D2 TB Network. PMID: 38245113.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    5. Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis. Clin Infect Dis. 2024 01 25; 78(1):154-163. Brümmer LE, Thompson RR, Malhotra A, Shrestha S, Kendall EA, Andrews JR, Phillips P, Nahid P, Cattamanchi A, Marx FM, Denkinger CM, Dowdy DW. PMID: 37623745; PMCID: PMC10810711.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Tuberculosis treatment monitoring tests during routine practice: study design guidance. Clin Microbiol Infect. 2024 Jan 03. MacLean EL, Zimmer AJ, den Boon S, Gupta-Wright A, Cirillo DM, Cobelens F, Gillespie SH, Nahid P, Phillips PP, Ruhwald M, Denkinger CM. PMID: 38182047.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Standards for clinical trials for treating TB. Int J Tuberc Lung Dis. 2023 Dec 01; 27(12):885-898. du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ. PMID: 38042969; PMCID: PMC10719894.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies. Stat Med. 2024 02 10; 43(3):501-513. Dufault SM, Crook AM, Rolfe K, Phillips PPJ. PMID: 38038137.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    9. Estimands for clinical endpoints in Tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial. Res Sq. 2023 Nov 09. Weir IR, Dufault SM, Phillips PP. PMID: 37986887; PMCID: PMC10659528.
      View in: PubMed   Mentions:
    10. Treatment-shortening regimens for tuberculosis: updates and future priorities. Breathe (Sheff). 2023 Sep; 19(3):230028. Saluzzo F, Adepoju VA, Duarte R, Lange C, Phillips PPJ. PMID: 37830101; PMCID: PMC10567072.
      View in: PubMed   Mentions: 2  
    11. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2023 10 18; 67(10):e0068323. Stemkens R, Jager Vd, Dawson R, Diacon AH, Narunsky K, Padayachee SD, Boeree MJ, van Beek SW, Colbers A, Coenen MJH, Svensson EM, Fuhr U, Phillips PPJ, Te Brake LHM, Aarnoutse RE, PanACEA consortium. PMID: 37768317; PMCID: PMC10583668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis. Trials. 2023 Jun 06; 24(1):382. Dierig A, Hoelscher M, Schultz S, Hoffmann L, Jarchow-MacDonald A, Svensson EM, Te Brake L, Aarnoutse R, Boeree M, McHugh TD, Wildner LM, Gong X, Phillips P, Minja LT, Ntinginya N, Mpagama S, Liyoyo A, Wallis RS, Sebe M, Mhimbira FA, Mbeya B, Rassool M, Geiter L, Cho YL, Heinrich N. PMID: 37280643; PMCID: PMC10243693.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    13. Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study. Clin Trials. 2023 10; 20(5):497-506. Rehal S, Cro S, Phillips PP, Fielding K, Carpenter JR. PMID: 37277978; PMCID: PMC10504812.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    14. A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials. Am J Respir Crit Care Med. 2023 05 15; 207(10):1376-1382. Kurbatova EV, Phillips PPJ, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R, Nhung NV, Pierre S, Musodza Y, Shenje J, Badal-Faesen S, Vilbrun SC, Waja Z, Peddareddy L, Scott NA, Yuan Y, Goldberg SV, Swindells S, Chaisson RE, Nahid P. PMID: 36790881; PMCID: PMC10595436.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    15. Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania. Pilot Feasibility Stud. 2023 Apr 01; 9(1):55. Mpagama SG, Mvungi HC, Mbelele PM, Semvua HH, Liyoyo AA, de Guex KP, Sloan D, Kibiki GS, Boeree M, Phillips PPJ, Heysell SK. PMID: 37005695; PMCID: PMC10066962.
      View in: PubMed   Mentions:
    16. Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects. Int J Antimicrob Agents. 2023 May; 61(5):106775. Koele SE, Phillips PPJ, Upton CM, van Ingen J, Simonsson USH, Diacon AH, Aarnoutse RE, Svensson EM. PMID: 36893811.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    17. Tuberculosis Molecular Bacterial Load Assay Reveals Early Delayed Bacterial Killing in Patients With Relapse. Clin Infect Dis. 2023 02 08; 76(3):e990-e994. Ntinginya NE, Bakuli A, Mapamba D, Sabiiti W, Kibiki G, Minja LT, Kuchaka D, Reither K, Phillips PPJ, Boeree MJ, Gillespie SH, Hoelscher M, Heinrich N, Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) Consortium. PMID: 35717643; PMCID: PMC9907486.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    18. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589. Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S, Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team. PMID: 36041016; PMCID: PMC10169427.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    19. Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine. AIDS. 2023 06 01; 37(7):1097-1101. Chaisson LH, Semitala FC, Nangobi F, Steinmetz S, Marquez C, Armstrong DT, Opira B, Kamya MR, Phillips PPJ, Dowdy DW, Yoon C. PMID: 36779500; PMCID: PMC10164049.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. To Err Is Human, to Forgive Is Pharmacodynamic. Am J Respir Crit Care Med. 2023 01 15; 207(2):127-129. Phillips PPJ, Stout JE. PMID: 36165624; PMCID: PMC9893336.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. A comparison of clinical development pathways to advance tuberculosis regimen development. BMC Infect Dis. 2022 Dec 09; 22(1):920. Chang V, Phillips PPJ, Imperial MZ, Nahid P, Savic RM. PMID: 36494644.
      View in: PubMed   Mentions: 2     Fields:    
    22. Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clin Infect Dis. 2022 09 10; 75(4):560-566. Podany AT, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, Badal-Faesen S, Dawson R, Johnson JL, Mayanja H, Lalloo U, Whitworth WC, Pettit A, Campbell K, Phillips PPJ, Bryant K, Scott N, Vernon A, Kurbatova EV, Chaisson RE, Dorman SE, Nahid P, Swindells S, Dooley KE, Fletcher CV. PMID: 34918028; PMCID: PMC9890454.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    23. Factors associated with screening failure and study withdrawal in multidrug-resistant TB. Int J Tuberc Lung Dis. 2022 09 01; 26(9):820-825. Schwalb A, Cachay R, Wright A, Phillips PPJ, Kaur P, Diacon AH, Ugarte-Gil C, Mitnick CD, Sterling TR, Gotuzzo E, Horsburgh CR. PMID: 35996282.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    24. Rethinking intercurrent events in defining estimands for tuberculosis trials. Clin Trials. 2022 10; 19(5):522-533. Pham TM, Tweed CD, Carpenter JR, Kahan BC, Nunn AJ, Crook AM, Esmail H, Goodall R, Phillips PP, White IR. PMID: 35850542; PMCID: PMC9523802.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial. Trials. 2022 May 12; 23(1):399. Semitala FC, Chaisson LH, Dowdy DW, Armstrong DT, Opira B, Aman K, Kamya M, Phillips PPJ, Yoon C. PMID: 35550621; PMCID: PMC9096738.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    26. Four-Month Rifapentine Regimens for Tuberculosis. Reply. N Engl J Med. 2022 03 17; 386(11):1095-1096. Phillips PPJ, Kurbatova EV, Dorman SE. PMID: 35294823.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Clinical Impact of the Line Probe Assay and Xpert® MTB/RIF Assay in the Presumptive Diagnosis of Drug-Resistant Tuberculosis in Brazil: A Pragmatic Clinical Trial. Rev Soc Bras Med Trop. 2022; 55:e0191. Kritski A, Oliveira MM, Almeida IN, Ramalho D, Andrade MKN, Carvalho M, Miranda PFC, Dalcolmo MP, Braga JU, Brígido T, Mesquita E, Dias C, Gambirasio A, Souza Filho JB, Detjen A, Phillips PPJ, Langley I, Fujiwara P, Squire SB. PMID: 35239898; PMCID: PMC8932318.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    28. MOVER approximated CV: A tool for quantifying precision in ratiometric droplet digital PCR assays. J Pharm Biomed Anal. 2022 Apr 01; 212:114664. Dide-Agossou C, Rossmassler K, Reid J, Purohit J, Savic RM, Nahid P, Phillips PPJ, Moore CM, Walter ND. PMID: 35192991; PMCID: PMC8923918.
      View in: PubMed   Mentions:    Fields:    
    29. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 12; 18(12):e1003875. Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. PMID: 34914696; PMCID: PMC8726462.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    30. Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials. Am J Respir Crit Care Med. 2021 11 01; 204(9):1086-1096. Imperial MZ, Phillips PPJ, Nahid P, Savic RM. PMID: 34346856; PMCID: PMC8663006.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    31. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651. Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Velásquez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD. PMID: 34563240; PMCID: PMC8465691.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    32. A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials. Trials. 2021 Aug 03; 22(1):515. Hills NK, Lyimo J, Nahid P, Savic RM, Lienhardt C, Phillips PPJ. PMID: 34344435; PMCID: PMC8329622.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    33. Optimising pyrazinamide for the treatment of tuberculosis. Eur Respir J. 2021 07; 58(1). Zhang N, Savic RM, Boeree MJ, Peloquin CA, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PPJ, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE, Tuberculosis Trials Consortium (TBTC) and Pan African Consortium for the Evaluation of Antituberculo. PMID: 33542052; PMCID: PMC8371453.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    34. Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin. Eur Respir J. 2021 07; 58(1). Te Brake LHM, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PPJ, Gillespie SH, Heinrich N, Hoelscher M, Dawson R, Diacon AH, Aarnoutse RE, Boeree MJ, PanACEA Consortium. PMID: 33542056; PMCID: PMC8411896.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    35. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 05 06; 384(18):1705-1718. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE, AIDS Clinical Trials Group, Tuberculosis Trials Consortium. PMID: 33951360; PMCID: PMC8282329.
      View in: PubMed   Mentions: 156     Fields:    Translation:HumansCellsCTClinical Trials
    36. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania. J Clin Microbiol. 2021 03 19; 59(4). Mbelele PM, Mpolya EA, Sauli E, Mtafya B, Ntinginya NE, Addo KK, Kreppel K, Mfinanga S, Phillips PPJ, Gillespie SH, Heysell SK, Sabiiti W, Mpagama SG. PMID: 33536294; PMCID: PMC8092737.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    37. The use of molecular genetic diagnostic tests to improve MDR TB treatment outcomes in Arkhangelsk Region. Tuberculosis and Lung Diseases. 2021; 99(8):21-26. Eliseev, P. I.; Maryandyshev, A. O.; Detjen, A.; Dacombe, R.; Squire, S. B.; Phillips, P.
    38. Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial. BMC Med. 2020 11 04; 18(1):314. Phillips PPJ, Van Deun A, Ahmed S, Goodall RL, Meredith SK, Conradie F, Chiang CY, Rusen ID, Nunn AJ. PMID: 33143704; PMCID: PMC7640464.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    39. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020 08 12; 15(1):65. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. PMID: 32787925; PMCID: PMC7425004.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    40. Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. Am J Respir Crit Care Med. 2020 07 15; 202(2):305-306. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. PMID: 32282235; PMCID: PMC7365358.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay. Thorax. 2020 07; 75(7):606-608. Sabiiti W, Azam K, Farmer ECW, Kuchaka D, Mtafya B, Bowness R, Oravcova K, Honeyborne I, Evangelopoulos D, McHugh TD, Khosa C, Rachow A, Heinrich N, Kampira E, Davies G, Bhatt N, Ntinginya EN, Viegas S, Jani I, Kamdolozi M, Mdolo A, Khonga M, Boeree MJ, Phillips PPJ, Sloan D, Hoelscher M, Kibiki G, Gillespie SH. PMID: 32354738; PMCID: PMC7361026.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    42. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med. 2020 03 01; 201(5):598-605. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. PMID: 31711306.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    43. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial. Bull World Health Organ. 2020 May 01; 98(5):306-314. Madan JJ, Rosu L, Tefera MG, van Rensburg C, Evans D, Langley I, Tomeny EM, Nunn A, Phillips PP, Rusen ID, Squire SB, STREAM study health economic evaluation collaborators. PMID: 32514196; PMCID: PMC7265936.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    44. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials. 2020 03; 90:105938. Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE, AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. PMID: 31981713; PMCID: PMC7307310.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    45. Q fever-the superstition of avoiding the word "quiet" as a coping mechanism: randomised controlled non-inferiority trial. BMJ. 2019 Dec 18; 367:l6446. Brookfield CR, Phillips PPJ, Shorten RJ. PMID: 31852676; PMCID: PMC7190014.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    46. Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. Eur Respir J. 2019 10; 54(4). Stagg HR, Bothamley GH, Davidson JA, Kunst H, Lalor MK, Lipman MC, Loutet MG, Lozewicz S, Mohiyuddin T, Abbara A, Alexander E, Booth H, Creer DD, Harris RJ, Kon OM, Loebinger MR, McHugh TD, Milburn HJ, Palchaudhuri P, Phillips PPJ, Schmok E, Taylor L, Abubakar I, London INH-R TB study group. PMID: 31371444; PMCID: PMC6785706.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    47. Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate. BMJ Open. 2019 09 30; 9(9):e030215. Morris TP, Jarvis CI, Cragg W, Phillips PPJ, Choodari-Oskooei B, Sydes MR. PMID: 31575572; PMCID: PMC6773317.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    48. A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply. N Engl J Med. 2019 09 12; 381(11):e22. Nunn AJ, Phillips PPJ. PMID: 31509688.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. BMC Pulm Med. 2019 Aug 14; 19(1):152. Tweed CD, Crook AM, Dawson R, Diacon AH, McHugh TD, Mendel CM, Meredith SK, Mohapi L, Murphy ME, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Gillespie SH. PMID: 31412895; PMCID: PMC6694514.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    50. STREAM: a pragmatic and explanatory trial for MDR-TB treatment. Lancet Infect Dis. 2019 06; 19(6):575-576. Abubakar I, Meredith S, Nunn AJ, Phillips PPJ, Rusen ID. PMID: 31122769.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening. Diagnostics (Basel). 2019 May 30; 9(2). Alipanah N, Shete PB, Nguyen H, Nguyen NV, Luu L, Pham T, Nguyen H, Nguyen P, Tran MC, Pham N, Phan H, Phillips PPJ, Cattamanchi A, Nahid P. PMID: 31151255; PMCID: PMC6627302.
      View in: PubMed   Mentions: 2  
    52. Protein binding of rifampicin is not saturated when using high-dose rifampicin. J Antimicrob Chemother. 2019 04 01; 74(4):986-990. Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM, PanACEA-MAMS-TB-01 Team. PMID: 30597025.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    53. Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. PLoS Med. 2019 03; 16(3):e1002767. Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ. PMID: 30901331; PMCID: PMC6430373.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    54. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019 03 28; 380(13):1201-1213. Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID, STREAM Study Collaborators. PMID: 30865791.
      View in: PubMed   Mentions: 140     Fields:    Translation:HumansCTClinical Trials
    55. Cost minimization analysis of line probe assay for detection of multidrug-resistant tuberculosis in Arkhangelsk region of Russian Federation. PLoS One. 2019; 14(1):e0211203. Bogdanova EN, Mariandyshev AO, Balantcev GA, Eliseev PI, Nikishova EI, Gaida AI, Enarson D, Detjen A, Dacombe R, Phillips PPJ, Squire SB, Gospodarevskaya E. PMID: 30695043; PMCID: PMC6350971.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    56. Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2019 Jan; 25(1):190. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. PMID: 30429542; PMCID: PMC7608289.
      View in: PubMed   Mentions: 1     Fields:    
    57. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018 11; 24(11):1708-1715. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. PMID: 30397355; PMCID: PMC6685538.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansCTClinical Trials
    58. Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrob Agents Chemother. 2018 10; 62(10). Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR. PMID: 30012767; PMCID: PMC6153781.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    59. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Infect Dis. 2018 07 11; 18(1):317. Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH. PMID: 29996783; PMCID: PMC6042413.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    60. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis. 2018 06 18; 67(1):34-41. Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R. PMID: 29917079; PMCID: PMC6005123.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    61. Rethinking non-inferiority: a practical trial design for optimising treatment duration. Clin Trials. 2018 10; 15(5):477-488. Quartagno M, Walker AS, Carpenter JR, Phillips PP, Parmar MK. PMID: 29871495; PMCID: PMC6136078.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    62. Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis. BMC Med. 2018 05 21; 16(1):73. Murthy SE, Chatterjee F, Crook A, Dawson R, Mendel C, Murphy ME, Murray SR, Nunn AJ, Phillips PPJ, Singh KP, McHugh TD, Gillespie SH, REMoxTB Consortium. PMID: 29779492; PMCID: PMC5961483.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    63. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018 04; 6(4):265-275. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D. PMID: 29595509; PMCID: PMC9017096.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    64. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med. 2018 03 28; 16(1):46. Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH. PMID: 29592805; PMCID: PMC5875008.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    65. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials. 2017 Nov 25; 18(1):563. Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR. PMID: 29178937; PMCID: PMC5702225.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    66. A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens. BMC Med. 2017 11 24; 15(1):207. Phillips PPJ, Mendel CM, Nunn AJ, McHugh TD, Crook AM, Hunt R, Bateson A, Gillespie SH. PMID: 29169355; PMCID: PMC5701316.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    67. Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis. BMC Med. 2017 10 27; 15(1):192. Murphy ME, Phillips PPJ, Mendel CM, Bongard E, Bateson ALC, Hunt R, Murthy S, Singh KP, Brown M, Crook AM, Nunn AJ, Meredith SK, Lipman M, McHugh TD, Gillespie SH, REMoxTB Consortium. PMID: 29073910; PMCID: PMC5658986.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    68. Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2017 11; 61(11). Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ, PanACEA Consortium. PMID: 28827417; PMCID: PMC5655063.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    69. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clin Trials. 2017 Oct; 14(5):451-461. Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, Phillips PP, Spears MR, Rowley S, Kaplan R, James ND, Maughan T, Paton N, Royston PJ. PMID: 28830236; PMCID: PMC5700799.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    70. Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil. BMC Infect Dis. 2017 08 15; 17(1):571. Ramalho DMP, Miranda PFC, Andrade MK, Brígido T, Dalcolmo MP, Mesquita E, Dias CF, Gambirasio AN, Ueleres Braga J, Detjen A, Phillips PPJ, Langley I, Fujiwara PI, Squire SB, Oliveira MM, Kritski AL, for Rede-TB Study group. PMID: 28810911; PMCID: PMC5558720.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    71. Setting Tuberculosis Regimen Development on a Firm Foundation. Clin Infect Dis. 2017 07 01; 65(1):55-56. Phillips PPJ. PMID: 28402531.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    72. Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. BMC Med. 2017 03 29; 15(1):71. Witney AA, Bateson AL, Jindani A, Phillips PP, Coleman D, Stoker NG, Butcher PD, McHugh TD, RIFAQUIN Study Team. PMID: 28351427; PMCID: PMC5371199.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    73. Methodological considerations in clinical trials for new MDR-TB treatment regimens. Int J Tuberc Lung Dis. 2016 12 01; 20(12):4-7. Phillips PPJ. PMID: 28240565.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    74. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017 01; 17(1):39-49. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M, PanACEA consortium. PMID: 28100438; PMCID: PMC5159618.
      View in: PubMed   Mentions: 154     Fields:    Translation:Humans
    75. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). Int J Geriatr Psychiatry. 2017 12; 32(12):1205-1216. Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R. PMID: 27739182; PMCID: PMC5724694.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    76. Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ Open. 2016 10 07; 6(10):e012594. Rehal S, Morris TP, Fielding K, Carpenter JR, Phillips PP. PMID: 27855102; PMCID: PMC5073571.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    77. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes. Trials. 2016 07 02; 17(1):309. Bratton DJ, Parmar MK, Phillips PP, Choodari-Oskooei B. PMID: 27369182; PMCID: PMC4930581.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    78. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2016 05; 47(5):1591-2. Berry C, Yates TA, Seddon JA, Phillips PP, du Cros P, North London TB Journal Club. PMID: 27132271.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    79. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLoS One. 2016; 11(4):e0152761. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, Ornstein T, Detjen A, Dacombe R, Gospodarevskaya E, Phillips PP, Mann G, Squire SB, Mariandyshev A. PMID: 27055269; PMCID: PMC4824472.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    80. World TB Day 2016: an interview with leading experts in tuberculosis research. BMC Med. 2016 Mar 23; 14:55. Phillips PP, Fletcher HA, Abubakar I, Lipman MC, McHugh TD. PMID: 27007648; PMCID: PMC4806503.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    81. A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Med. 2016 Mar 23; 14:51. Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M. PMID: 27004726; PMCID: PMC4804526.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    82. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 2016 Mar; 20(3):290-4. Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P. PMID: 27046707; PMCID: PMC4843774.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    83. Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Med. 2016 Feb 23; 14:36. Phillips PP, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, Diacon AH, Gillespie SH. PMID: 26905218; PMCID: PMC4765164.
      View in: PubMed   Mentions: 1     Fields:    
    84. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Med. 2016 Feb 04; 14:19. Phillips PP, Mendel CM, Burger DA, Crook AM, Crook A, Nunn AJ, Dawson R, Diacon AH, Gillespie SH. PMID: 26847437; PMCID: PMC4743210.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    85. Challenges in the clinical assessment of novel tuberculosis drugs. Adv Drug Deliv Rev. 2016 07 01; 102:116-22. Dooley KE, Phillips PP, Nahid P, Hoelscher M. PMID: 26827911; PMCID: PMC4903928.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    86. Infectious Disease Epidemiology. Abubakar I, Stagg HR, Cohen T, Rodrigues LC (Eds.). Clinical Trials. 2016. Phillips PPJ & Nunn AJ. View Publication.
    87. DOOR/RADAR: A Gateway Into the Unknown? Clin Infect Dis. 2016 Mar 15; 62(6):814-5. Phillips PP, Morris TP, Walker AS. PMID: 26658302.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    88. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2015 Dec; 14(12):1171-81. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown RG, Banerjee S, Adams J, Johnson T, Bentham P, Phillips PP. PMID: 26515660.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    89. Reducing relapse in tuberculosis treatment. Int J Tuberc Lung Dis. 2015 Oct; 19(10):1263-4. Nunn AJ, Phillips PP, Abubakar I. PMID: 26459549.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    90. Comments on 'A modest proposal for dropping poor arms in clinical trials' by Proschan and Dodd. Stat Med. 2015 Aug 15; 34(18):2678-9. Bratton DJ, Choodari-Oskooei B, Phillips PP, Sydes MR, Parmar MK. PMID: 26147569.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    91. A Step toward an Optimized Rifampin Dose Completed. Am J Respir Crit Care Med. 2015 Aug 15; 192(4):525-6. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE. PMID: 26278799.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    92. Adaptive clinical trials in tuberculosis: applications, challenges and solutions. Int J Tuberc Lung Dis. 2015 Jun; 19(6):626-34. Davies GR, Phillips PP, Jaki T. PMID: 25946350.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    93. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015 May 01; 191(9):1058-65. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE, PanACEA Consortium. PMID: 25654354.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCTClinical Trials
    94. Safe and effective treatment for patients with isoniazid drug resistance. Int J Tuberc Lung Dis. 2015 Apr; 19(4):494-5. Phillips PP, Lipman MC. PMID: 25860010.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    95. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2015 02 05; 372(6):577. Gillespie SH, Mendel CM, REMoxTB Consortium. PMID: 25651256.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    96. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2015 02 05; 372(6):576. Alffenaar JW, Gumbo T, Aarnoutse R. PMID: 25651257.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    97. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2015 02 05; 372(6):577. Sellier PO, Clevenbergh P, Bergmann JF. PMID: 25651258.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    98. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother. 2015 May; 70(5):1558-66. Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH, Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA), Pan African Consortium for the Evaluation of Antituberculosis Antibiotics PanACEA. PMID: 25630641.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    99. Shortening treatment of tuberculosis: lessons from fluoroquinolone trials. Lancet Infect Dis. 2015 Feb; 15(2):141-3. Nimmo C, Lipman M, Phillips PP, McHugh T, Nunn A, Abubakar I. PMID: 25749057.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    100. The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. J Antimicrob Chemother. 2015 Feb; 70(2):448-55. Bowness R, Boeree MJ, Aarnoutse R, Dawson R, Diacon A, Mangu C, Heinrich N, Ntinginya NE, Kohlenberg A, Mtafya B, Phillips PP, Rachow A, Plemper van Balen G, Gillespie SH. PMID: 25344806.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    101. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014 Oct 23; 371(17):1599-608. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA, RIFAQUIN Trial Team. PMID: 25337749; PMCID: PMC4233406.
      View in: PubMed   Mentions: 195     Fields:    Translation:HumansCellsCTClinical Trials
    102. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014 Sep 09; 15:353. Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, Squire SB, Madan J, Meredith SK. PMID: 25199531; PMCID: PMC4164715.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    103. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23; 371(17):1577-87. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ, REMoxTB Consortium. PMID: 25196020; PMCID: PMC4277680.
      View in: PubMed   Mentions: 281     Fields:    Translation:HumansCellsCTClinical Trials
    104. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014 Sep; 33(9):993. Turkova A, Seddon JA, Nunn AJ, Gibb DM, Phillips PP. PMID: 25361029; PMCID: PMC4138004.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    105. The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment. J Clin Microbiol. 2014 Aug; 52(8):3064-7. Honeyborne I, Mtafya B, Phillips PP, Hoelscher M, Ntinginya EN, Kohlenberg A, Rachow A, Rojas-Ponce G, McHugh TD, Heinrich N, Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics. PMID: 24871215; PMCID: PMC4136187.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    106. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis. 2014 Apr; 14(4):327-40. Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ. PMID: 24670627.
      View in: PubMed   Mentions: 125     Fields:    Translation:Humans
    107. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis. BMC Med Res Methodol. 2013 Nov 14; 13:139. Bratton DJ, Phillips PP, Parmar MK. PMID: 24229079; PMCID: PMC3840569.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    108. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014 Jan 01; 92(1):68-74. Brigden G, Nyang'wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M. PMID: 24391302; PMCID: PMC3865549.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    109. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2013 Aug; 1(6):462-70. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M, Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). PMID: 24429244.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCells
    110. An analysis with serious flaws. Clin Infect Dis. 2013 Oct; 57(7):1064-5. Nunn AJ, Phillips PP. PMID: 23811419.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    111. Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months? Int J Tuberc Lung Dis. 2013 Jun; 17(6):807-9. Phillips PP, Nunn AJ, Paton NI. PMID: 23676166.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    112. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One. 2013; 8(5):e63840. Phillips PP, Fielding K, Nunn AJ. PMID: 23667677; PMCID: PMC3648512.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    113. Treatment of pulmonary tuberculosis. Curr Opin Pulm Med. 2013 May; 19(3):273-9. Nunn A, Phillips PP, Abubakar I. PMID: 23528955.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    114. Randomized clinical trials to identify optimal antibiotic treatment duration. Trials. 2013 Mar 28; 14:88. Horsburgh CR, Shea KM, Phillips P, Lavalley M. PMID: 23536969; PMCID: PMC3622584.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    115. Reply to Dodd and Proschan. J Infect Dis. 2013 Feb 01; 207(3):544-5. Phillips PP, Bratton DJ, Nunn AJ, Hoelscher M. PMID: 23175768.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    116. When inferiority meets non-inferiority: implications for interim analyses. Clin Trials. 2012 Oct; 9(5):605-9. Bratton DJ, Williams HC, Kahan BC, Phillips PP, Nunn AJ. PMID: 22796636.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    117. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis. 2012 May 15; 205 Suppl 2:S250-7. Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelscher M. PMID: 22448027.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    118. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012 Mar 08; 366(10):893-903. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. PMID: 22397651.
      View in: PubMed   Mentions: 213     Fields:    Translation:Humans
    119. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med. 2011 Oct 15; 184(8):972-9. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W, National Institutes of Health, Centers for Disease Control and Prevention. PMID: 21737585; PMCID: PMC3208659.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    120. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J Clin Microbiol. 2011 Nov; 49(11):3905-11. Honeyborne I, McHugh TD, Phillips PP, Bannoo S, Bateson A, Carroll N, Perrin FM, Ronacher K, Wright L, van Helden PD, Walzl G, Gillespie SH. PMID: 21900522; PMCID: PMC3209113.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    121. Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010 Dec; 14(12):1596-602. Perrin FM, Woodward N, Phillips PP, McHugh TD, Nunn AJ, Lipman MC, Gillespie SH. PMID: 21144246.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    122. Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry. 2011 Aug; 26(8):812-7. Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, Bentham P, Burns A, Ballard C, Holmes C, McKeith I, Barber R, Dening T, Ritchie C, Jones R, Baldwin A, Passmore P, Findlay D, Hughes A, Macharouthu A, Banerjee S, Jones R, Knapp M, Brown RG, Jacoby R, Adams J, Griffin M, Gray R. PMID: 20848576.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    123. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinb). 2010 Sep; 90(5):301-5. Dhillon J, Andries K, Phillips PP, Mitchison DA. PMID: 20732832.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    124. Challenges of Phase III study design for trials of new drug regimens for the treatment of TB. Future Med Chem. 2010 Aug; 2(8):1273-82. Phillips PP, Nunn AJ. PMID: 21426018.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    125. Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia. Antimicrob Agents Chemother. 2010 Sep; 54(9):3756-62. Mwenya DM, Charalambous BM, Phillips PP, Mwansa JC, Batt SL, Nunn AJ, Walker S, Gibb DM, Gillespie SH. PMID: 20585110; PMCID: PMC2934996.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    126. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2010 Feb; 10(2):69-70; author reply 70-1. Phillips PP, Davies GR, Mitchison DA. PMID: 20113973.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    127. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis. 2010 Feb; 14(2):241-2. Nunn AJ, Phillips PP, Mitchison DA. PMID: 20074418.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    128. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials. 2009 Jul 24; 10:57. Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, Brown R, Burns A, Dening T, Findlay D, Gray R, Griffin M, Holmes C, Hughes A, Jacoby R, Johnson T, Jones R, Knapp M, Lindesay J, McKeith I, McShane R, Macharouthu A, O'Brien J, Onions C, Passmore P, Raftery J, Ritchie C, Howard R, DOMINO-AD team. PMID: 19630974; PMCID: PMC2723100.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    129. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb). 2008 Aug; 88 Suppl 1:S85-92. Nunn AJ, Phillips PP, Gillespie SH. PMID: 18762156.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    130. Biomarkers and surrogate end points in clinical trials of tuberculosis treatment. J Infect Dis. 2007 Aug 15; 196(4):648-9; author reply 649-50. Davies GR, Phillips PP, Nunn AJ. PMID: 17624855.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    131. Cannabis in postoperative pain: a pharmacokinetic study. British Journal of Anaesthesia. 2004; 93(4):609-610. A. Holdcroft, C. Dore, P. Phillips, M. Maze and M. Hanna .
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Patrick's Networks
    Concepts (264)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (15)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.